Global Blood Therapeutics Inc $ 54.54 -2.04 (-3.61%)
Volume:
370,735
Avg Vol (1m):
813,902
Market Cap $:
3.35 Bil
Enterprise Value $:
2.97 Bil
P/E (TTM):
0.00
P/B:
6.75
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 3.4 | ||
| Equity-to-Asset | 0.69 | ||
| Debt-to-Equity | 0.32 | ||
| Debt-to-EBITDA | -0.56 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 7.2 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -632.24 | ||
| Net Margin % | -600.05 | ||
| ROE % | -48.37 | ||
| ROA % | -38.13 | ||
| ROC (Joel Greenblatt) % | -472.21 | ||
| 3-Year EBITDA Growth Rate | -24.8 | ||
| 3-Year EPS without NRI Growth Rate | -22.6 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 6.75 | ||
| PS Ratio | 69.88 | ||
| EV-to-EBIT | -9.99 | ||
| EV-to-EBITDA | -10.4 | ||
| EV-to-Revenue | 62.28 | ||
| Current Ratio | 8.56 | ||
| Quick Ratio | 8.17 | ||
| Days Inventory | 10345.94 | ||
| Days Sales Outstanding | 95.37 | ||
| Days Payable | 4056.35 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.76 | ||
| Earnings Yield (Greenblatt) % | -9.99 |